Treatment of preeclampsia
Reading File
Now I'll run parallel searches across the medical library and PubMed simultaneously.
Finding Sources
Searching PubMed
"preeclampsia"[MeSH Terms] AND "treatment"[MeSH Terms]
Reading File
Finding Sources
Searching PubMed
preeclampsia management antihypertensive
I have rich content from the Brenner & Rector Kidney textbook. Let me read more of that block and pull content from Tintinalli's and the Creasy & Resnik textbook for completeness.
Reading File
Reading File
I hit references at offset 3071 — the main treatment content was in the earlier truncated output. Let me re-read the key treatment sections from Brenner & Rector more carefully and also pull content from other key textbooks.
Reading File
Reading File
Excellent — I now have comprehensive content from multiple authoritative textbooks. Let me also quickly get the antihypertensive drug table from one more source and fetch the web for any current guideline updates.
Finding Sources
Searching the Web
preeclampsia treatment guidelines 2024 2025 ACOG delivery antihypertensive
I now have comprehensive, multi-source content to deliver a thorough answer. Let me compose it.
Treatment of Preeclampsia
Preeclampsia is defined by new-onset hypertension (≥140/90 mmHg) after 20 weeks of gestation, with or without proteinuria, in a previously normotensive woman. The only definitive treatment is delivery of the placenta — all other measures are temporizing strategies aimed at stabilizing the mother while maximizing fetal maturity.
1. Delivery: Definitive Treatment
The timing of delivery must balance maternal risk against fetal prematurity risk.
| Gestational Age | Recommendation |
|---|---|
| < 24 weeks | Termination generally recommended; perinatal mortality > 80% even with expectant management |
| 24–34 weeks | Expectant management appropriate if clinically stable; intensive maternal and fetal monitoring required |
| 34–37 weeks | Individualized; expectant management to prolong pregnancy vs. delivery risk/benefit assessment |
| ≥ 37 weeks | Immediate delivery almost always indicated (HYPITAT trial: maternal risks significantly reduced without added perinatal risk) |
Indications for urgent delivery regardless of gestational age:
- Worsening renal or hepatic function
- Progressive thrombocytopenia
- Uncontrollable hypertension
- Neurologic symptoms (severe headache, visual disturbance, clonus)
- Non-reassuring fetal testing or suspected abruption
— Comprehensive Clinical Nephrology 7e; Brenner & Rector's The Kidney
2. Blood Pressure Management
The goal is not tight long-term BP control as in the general population — it is to prevent acute cerebrovascular complications while preserving uteroplacental perfusion. Aggressive BP lowering can cause fetal distress by reducing an already-compromised placental blood flow.
Threshold to treat: BP ≥ 150–160 mmHg systolic or ≥ 100–110 mmHg diastolic (risk of maternal cerebral hemorrhage above these levels).
Acute (Severe Hypertension) — First-Line Agents
| Drug | Route | Dose |
|---|---|---|
| Labetalol (α/β-blocker) | IV | 20 mg bolus; repeat 40–80 mg every 10–30 min; max 300 mg |
| Hydralazine | IV | 5–10 mg bolus every 20 min |
| Nifedipine (immediate release) | Oral | 10–20 mg; preferred when IV access unavailable |
IV labetalol and hydralazine have long been considered first-line for acute-onset severe hypertension in pregnancy and the postpartum period. Immediate-release oral nifedipine is also recommended as a first-line option. For pulmonary edema in the setting of preeclampsia, IV nitroglycerin should be considered.
— Fuster & Hurst's The Heart 15e; Barash Clinical Anesthesia 9e; Swanson's Family Medicine Review
Chronic/Maintenance Oral Agents
- Methyldopa — longest safety record in pregnancy; first choice for maintenance
- Labetalol — widely used alternative
- Modified-release nifedipine — well tolerated for maintenance
Agents to avoid in pregnancy: ACE inhibitors, ARBs, direct renin inhibitors (teratogenic/fetotoxic).
3. Seizure Prophylaxis: Magnesium Sulfate
Magnesium sulfate is the drug of choice for prevention and treatment of eclamptic seizures — superior to diazepam and phenytoin.
Key evidence:
- The Magpie Trial (>10,000 women, 33 countries): MgSO₄ reduced eclamptic seizure incidence by 50% (0.8% vs. 1.9% vs. placebo).
- ACOG recommends MgSO₄ for preeclampsia with severe features and for eclampsia.
Dosing:
- Loading dose: 4–6 g IV over 15–20 minutes
- Maintenance: 2 g/hour continuous infusion for ≥ 24 hours
- In renal insufficiency: reduce to 2 g IV bolus and monitor serum levels
Monitoring for toxicity (especially in renal impairment):
| Serum Mg Level | Effect |
|---|---|
| 5–9 mg/dL | Therapeutic range |
| Loss of deep tendon reflexes | Early toxicity warning |
| Respiratory depression | Serious toxicity |
| Cardiac arrest | Severe toxicity |
Monitor: patellar reflexes, respiratory rate (keep ≥ 12/min), oxygen saturation, urine output. Calcium gluconate (1 g IV) is the antidote for magnesium toxicity.
Withholding seizure prophylaxis in women with preeclampsia without severe features is associated with an extremely low seizure risk and avoids drug toxicity (which occurs in up to 25% of treated women).
— Brenner & Rector's The Kidney; Comprehensive Clinical Nephrology 7e; Tintinalli's Emergency Medicine
4. HELLP Syndrome Management
HELLP (Hemolysis, Elevated Liver enzymes, Low Platelets) is a severe variant.
- Initial management: IV magnesium + BP control + hospital admission
- Definitive: delivery (especially at ≥ 34 weeks)
- Corticosteroids (e.g., betamethasone) can be given <34 weeks to improve fetal lung maturity and may be used to stabilize the patient
- Platelet transfusion: generally given for platelets < 20–30 × 10⁹/L to facilitate safe delivery; avoid at higher counts (consumption, not production failure)
- Correct coagulopathy; use concentrated preparations cautiously to avoid fluid overload
— Tintinalli's Emergency Medicine; Comprehensive Clinical Nephrology 7e
5. Fluid Management
Preeclampsia is a volume-contracted, not volume-depleted state. Increased capillary permeability makes IV fluid expansion hazardous.
- Fluid restriction to approximately 85 mL/hour in severe preeclampsia reduces maternal morbidity and mortality
- Aggressive volume expansion risks pulmonary edema
- Central venous pressure monitoring is not routinely indicated
— Comprehensive Clinical Nephrology 7e
6. Postpartum Considerations
- Hypertension may worsen or first manifest in the first 48–72 hours postpartum
- Continue antihypertensive therapy as needed; treat BP ≥ 150/100 mmHg
- Magnesium infusion is typically continued for 24–48 hours postpartum
- NSAIDs (e.g., ibuprofen) used for postpartum analgesia may worsen hypertension; consider acetaminophen instead
7. Anesthetic Considerations
- Epidural/spinal analgesia is preferred (avoids hypertensive response to laryngoscopy with general anesthesia)
- Platelet count must be assessed before neuraxial block (threshold varies by institution, typically ≥ 70–80 × 10⁹/L)
- General anesthesia requires careful RSI to blunt the hypertensive intubation response (e.g., esmolol, remifentanil, or IV labetalol pre-induction)
— Morgan & Mikhail's Clinical Anesthesiology 7e; Barash Clinical Anesthesia 9e
Summary
| Intervention | Drug/Approach | Target |
|---|---|---|
| Definitive cure | Delivery | ≥37 wk: immediate; <37 wk: individualize |
| Acute BP control | Labetalol IV / Hydralazine IV / Nifedipine PO | SBP < 160, DBP < 110 |
| Seizure prophylaxis | MgSO₄ 4–6 g loading → 2 g/h infusion | Severe features present |
| Maintenance BP | Methyldopa / Labetalol / Nifedipine-LA | Avoid ACEi, ARBs |
| Fluid management | Restrict to ~85 mL/h | Prevent pulmonary edema |
| Platelet support | Transfuse if < 20–30 × 10⁹/L | Safe delivery |
Recent evidence note: A 2024 systematic review and meta-analysis (PMID 38763516) summarizing the 2023 SOMANZ hypertension in pregnancy guideline confirms labetalol, nifedipine, and methyldopa as first-line agents, consistent with current textbook guidance.
This is a shared conversation. Sign in to Orris to start your own chat.